{
    "organizations": [],
    "uuid": "38f2f3ffa621ec41da50d863de60ab700f520e20",
    "author": "",
    "url": "https://www.reuters.com/article/brief-interpace-diagnostics-enters-agree/brief-interpace-diagnostics-enters-agreement-with-integrated-health-systems-idUSFWN1RV0G7",
    "ord_in_thread": 0,
    "title": "BRIEF-Interpace Diagnostics Enters Agreement With Integrated Health Systems",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 40 PM / Updated 13 minutes ago BRIEF-Interpace Diagnostics Enters Agreement With Integrated Health Systems Reuters Staff \nApril 18 (Reuters) - Interpace Diagnostics Group Inc : \n* INTERPACE DIAGNOSTICS ENTERS AGREEMENT WITH ONE OF THE LARGEST, INTEGRATED HEALTH SYSTEMS IN THE US \n* INTERPACE DIAGNOSTICS-AGREEMENT ENABLES ALL PHYSICIANS ACROSS BJC SYSTEM ACCESS TO BOTH THYGENX, THYRAMIR FOR PATIENTS WITH INDETERMINATE THYROID NODULES Source text for Eikon: Further company coverage:",
    "published": "2018-04-18T15:36:00.000+03:00",
    "crawled": "2018-04-18T16:04:10.034+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "pm",
        "updated",
        "minute",
        "ago",
        "diagnostics",
        "enters",
        "agreement",
        "integrated",
        "health",
        "system",
        "reuters",
        "staff",
        "april",
        "reuters",
        "interpace",
        "diagnostics",
        "group",
        "inc",
        "interpace",
        "diagnostics",
        "enters",
        "agreement",
        "one",
        "largest",
        "integrated",
        "health",
        "system",
        "u",
        "interpace",
        "enables",
        "physician",
        "across",
        "bjc",
        "system",
        "access",
        "thygenx",
        "thyramir",
        "patient",
        "indeterminate",
        "thyroid",
        "nodule",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}